Education
About Us
Working with TipRanks
Follow Us
Perspective Therapeutics (CATX)
:CATX
CATX Stock Chart & Stats
$2.21
-$0.13(-3.36%)
At close: 4:00 PM EST
$2.21
-$0.13(-3.36%)
Day’s Range― - ―
52-Week Range$1.60 - $5.39
Previous CloseN/A
Volume311.62K
Average Volume (3M)1.76M
Market Cap
$152.39M
Enterprise Value$84.01M
Total Cash (Recent Filing)$191.58M
Total Debt (Recent Filing)$3.57M
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Mar 26, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding74,337,990
10 Day Avg. Volume1,616,026
30 Day Avg. Volume1,762,003
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.71
Price to Sales (P/S)0.00
P/FCF Ratio-2.83
Enterprise Value/Market Cap0.55
Enterprise Value/Revenue145.85
Enterprise Value/Gross Profit-97.12
Enterprise Value/Ebitda-0.73
Forecast
1Y Price Target
$11.92Price Target Upside439.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-1.23
Revenue Forecast (FY)$1.06M
Bulls Say, Bears Say
Bulls Say
Acquisition PotentialCATX is considered a prime acquisition target with multiple Big Pharma players advancing radiopharmaceutical pipelines.
Clinical Trial ProgressPerspective Therapeutics presented an update from their Phase 1/2a study investigating their Pb212-based SSTR2-targeting VMT-α-NET in patients with neuroendocrine tumors, showing a confirmed 35% objective response rate among patients with at least 9 months of follow-up.
Financial PositionPerspective ended with ~$174M in cash, cash equivalents, and marketable securities, which provides a runway into late 2026.
Bears Say
Competitive EnvironmentIncreased competition may impact commercial adoption of VMT-α-NET in NETs.
Efficacy ConcernsVMT-α-NET's efficacy is lower than competitor SNY/OranoMed's 212Pb-DOTAMTATE.
Stock PerformanceCATX stock is down ~26% following updated data for the VMT-a-NET program in NETs at the ESMO conference.
Perspective Therapeutics News
CATX FAQ
What was Perspective Therapeutics’s price range in the past 12 months?
Perspective Therapeutics lowest stock price was $1.60 and its highest was $5.39 in the past 12 months.
What is Perspective Therapeutics’s market cap?
Perspective Therapeutics’s market cap is $152.39M.
When is Perspective Therapeutics’s upcoming earnings report date?
Perspective Therapeutics’s upcoming earnings report date is Mar 26, 2026 which is in 111 days.
How were Perspective Therapeutics’s earnings last quarter?
Perspective Therapeutics released its earnings results on Nov 10, 2025. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.321 by -$0.029.
Is Perspective Therapeutics overvalued?
According to Wall Street analysts Perspective Therapeutics’s price is currently Undervalued.
Does Perspective Therapeutics pay dividends?
Perspective Therapeutics does not currently pay dividends.
What is Perspective Therapeutics’s EPS estimate?
Perspective Therapeutics’s EPS estimate is -0.36.
How many shares outstanding does Perspective Therapeutics have?
Perspective Therapeutics has 74,337,990 shares outstanding.
What happened to Perspective Therapeutics’s price movement after its last earnings report?
Perspective Therapeutics reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.321. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Perspective Therapeutics?
Currently, no hedge funds are holding shares in CATX
Perspective Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.92 (439.37% Upside)
$11.92 (439.37% Upside)
Blogger Sentiment
Bullish
CATX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 45.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $42.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.5%
Last 30 Days ▲ 8.2%
Last 30 Days ▲ 8.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.75%
12-Months-Change
Fundamentals
Return on Equity
-37.24%
Trailing 12-Months
Asset Growth
-24.63%
Trailing 12-Months
Company Description
Perspective Therapeutics
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
CATX Stock 12 Month Forecast
Average Price Target
$11.92
▲(439.37% Upside)
Technical Analysis
Ownership Overview
2.52% Insiders
17.77% Mutual Funds
5.62% Other Institutional Investors
65.78% Public Companies and Individual Investors